Adjuvant 5-Fluorouracil and BCNU Chemotherapy in Gastric Cancer: 3-Year Results

  • P. Schlag
  • W. Schreml
  • W. Gaus
  • C. Herfarth
  • M. M. Linder
  • W. Queisser
  • M. Trede
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 80)

Summary

One hundred-three patients with a potentially curative operation of a histologically proven gastric cancer were randomly assigned to a control and chemotherapy group after stratification according to tumor stage II and III. Chemotherapy courses with 5-fluorouracil (10 mg/kg/day) and BCNU (40 mg/m2/day) for 5 days were administered eight times in 6–8 week intervals. Age, sex, and tumor location were matched in the chemotherapy and control groups. Five patients declined treatment after randomization. Three years after initiating the study, the tumor has recurred in 38 of the 103 patients. There were 21 recurrences of 54 controls and 14 recurrences of 44 patients who received chemotherapy, and 17 and ten deaths, respectively, due to tumor relapse. The results of our study to data show a high degree of statistical probability that adjuvant chemotherapy with the regime used has no influence on the recurrence-free interval and survival time in gastric cancer.

Keywords

Adenocarcinoma Diarrhea Stratification Thrombocytopenia Pyrimidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carter SK, Comis RL (1977) Gastric cancer: Current status of treatment. J Natl Cancer Inst 58:567–578PubMedGoogle Scholar
  2. 2.
    Dixon WJ, Longmire WP, Holden WD (1971) Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal cancer: Ten-year follow-up. Ann Surg 173:26–39PubMedCrossRefGoogle Scholar
  3. 3.
    Engström P (to be published) Adjuvant therapy of gastric carcinoma: ECOG protocol comparing 5-FU plus MeCCNU versus untreated control. EORTC Symposium on Progress and Perspectives in the Treatment of Gastrointestinal Tumors, Brussels. Eur J CancerGoogle Scholar
  4. 4.
    Fujimoto S, Akao T, Itoh B, Koshizuka I, Koyano K, Kitsukawa Y, Takahashi M, Minami T, Ishigami H, Miyazaki M, Amamiya K, Ohyama Y, Ono K, Kure M, Itoh K, Hikosaka T (1977) Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Ann Surg 185:462–466PubMedCrossRefGoogle Scholar
  5. 5.
    Gilbertsen VA (1969) Results of treatment of stomach cancer. An appraisal of efforts for more extensive surgery and a report of 1,983 cases. Cancer 23: 1305—1308PubMedCrossRefGoogle Scholar
  6. 6.
    Goffin IC (to be published) Controlled clinical trial for the treatment of patients with gastric cancer using surgery, radiotherapy and chemotherapy. Preliminary results. EORTC Symposium on Progress and Perspectives in the Treatment of Gastrointestinal Tumors, Brussels. Eur J CancerGoogle Scholar
  7. 7.
    Herfarth C, Schlag P (eds) (1979) Gastric cancer. Springer, Berlin Heidelberg New YorkGoogle Scholar
  8. 8.
    Karrar K (1972) Importance of dose schedules in adjuvant chemotherapy. Cancer Chemother Rep 56:35–45PubMedGoogle Scholar
  9. 8a.
    Kovach JS, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1974) A controlled study of combined l,3-bis-(2-chlorethyl)-l-nitrosurea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33:563–567PubMedCrossRefGoogle Scholar
  10. 9.
    Longmire WP (1977) Gewandelte Aspekte des Magenkarzinoms. Münch Med Wochenschr 119:613–616Google Scholar
  11. 10.
    Merkle P, Schlag P, Herfarth C (1979) Aktuelle Aspekte bei der Therapie des Magenkarzinoms. Zentralbl Chir 104:1111–1116PubMedGoogle Scholar
  12. 11.
    Moertel CG (1978) Chemotherapy of gastrointestinal cancer. N Engl J Med 299:1049–1052PubMedCrossRefGoogle Scholar
  13. 12.
    Nakazato H, Imanaga H (1979) Results of surgery for gastric cancer and effect of adjuvant chemotherapy. In: Herfarth C, Schlag P (eds) Gastric cancer. Springer, Berlin Heidelberg New York, pp 344–356CrossRefGoogle Scholar
  14. 13.
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mante N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trilas requiring prolonged observation of each patient. Br J Cancer 35:1–39PubMedCrossRefGoogle Scholar
  15. 14.
    Schlag P, Merkle P, Herfarth C (1979) Neue Aspekte in der Konzeption adjuvanter und nachsorgender Therapie des Magencarcinoms? Chirurg 50:432–435Google Scholar
  16. 15.
    Taguchi T, Hattori T, Inoue K, Kondo T, Ichiji I, Kikuchi K, Sugie S, Inokuchi K (1979) Multihospital randomized study on adjuvant chemotherapy with mitomycin + Futraful for gastric cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer II. Grune & Stratton, New York London Toronto Sydney San Francisco, pp 581–586Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1982

Authors and Affiliations

  • P. Schlag
    • 1
  • W. Schreml
    • 1
  • W. Gaus
    • 1
  • C. Herfarth
    • 1
  • M. M. Linder
    • 1
  • W. Queisser
    • 1
  • M. Trede
    • 1
  1. 1.Abteilung für Allgemeine ChirurgieUniversität UlmUlm-SafranbergGermany

Personalised recommendations